Safety issues plague popular anticoagulant

The safety of the anticoagulant drug dabigatran is in question after an investigation found serious risks.

It’s now a case of user beware say scientists, who found the drug’s fickle pharmacokinetics can cause a fivefold variation of plasma concentration that may put some patients with atrial fibrillation at risk of serious bleeding, and leave others untreated for stroke risk.

The new class of drug marketed as Pradaxa and listed on the PBS promised safety and